Compositions for treating a sleep disorder or modifying or improving the sleep-wake cycle in a subject are disclosed herein. In some examples, the composition can comprise one or more sleep promoting active agents, one or more sleep quality active agents, one or more sleep recovery active agents, and optionally one or more next day active agents. The composition can provide an immediate burst release of the one or more sleep promoting active agents, a delayed burst or delayed sustained release of the one or more sleep quality active agents, a delayed burst or delayed sustained release of the one or more sleep recovery active agents, and a delayed burnt or delayed sustained release of the one or more next day active agents. The composition can be provided as a daily oral uni-dosage form. Methods of making and using the compositions are also provided.

This disclosure relates to methods of inducing adipocyte browning, supporting metabolic flexibility, and/or reducing detrimental WAT deposition or reducing WAT dysfunction in a subject by administering extensively hydrolyzed casein and/or fractions N thereof (eHC) to the subject, and/or by administering a long chain polyunsaturated fatty acid (e.g., docosahexaenoic acid and/or arachidonic acid) to the subject.

A method of fabricating an electronic power module by additive manufacturing, the electronic module including a substrate having an electrically insulating plate presenting opposite first and second faces, with a first metal layer arranged directly on the first face of the insulating plate, and a second metal layer arranged directly on the second face of the insulating plate. At least one of the metal layers is made by a step of depositing a thin layer of copper and a step of annealing the metal layer, and the method further includes a step of forming at least one thermomechanical transition layer on at least one of the first and second metal layers, the at least one thermomechanical transition layer including a material presenting a coefficient of thermal expansion that is less than that of the metal of the metal layer.

The method of making a hydrolyzed collagen gel is a manufacturing method for producing a hydrolyzed collagen gel to be used as a topical wound treatment. A first volume of purified water is initially heated to a temperature ranging from about 71 C. to about 77 C., and a hydrolyzed type I collagen powder is then mixed into the heated purified water to form a first mixture. An additive is mixed into the first mixture to form a second mixture, where the additive may be native collagen, at least one amino acid, least one therapeutic agent, gelatin, whey, hydrolyzed whey, polysulfated glycosaminoglycan, a glucosamine salt, glutamine, glycosaminoclycans, zinc, silver oxide alginates, cellulose, honey, mushroom extract and combinations thereof. A second volume of purified water is then added to the second mixture to form the hydrolyzed collagen gel product. Mixing is performed as a continuous, recirculating, temperature-monitored and temperature-maintained process.

The method of making a hydrolyzed collagen gel is a manufacturing method for producing a hydrolyzed collagen gel to be used as a topical wound treatment. A first volume of purified water is initially heated to a temperature ranging from about 71 C. to about 77 C., and a hydrolyzed type I collagen powder is then mixed into the heated purified water to form a first mixture. An additive is mixed into the first mixture to form a second mixture, where the additive may be native collagen, at least one amino acid, least one therapeutic agent, gelatin, whey, hydrolyzed whey, polysulfated glycosaminoglycan, a glucosamine salt, glutamine, glycosaminoclycans, zinc, silver oxide alginates, cellulose, honey, mushroom extract and combinations thereof. A second volume of purified water is then added to the second mixture to form the hydrolyzed collagen gel product. Mixing is performed as a continuous, recirculating, temperature-monitored and temperature-maintained process.

This invention relates to the administration of a combination of TGF- and one or more peptides comprising specific sequences of -lacto-globulin. The peptides are hypoallergenic but retain the capability to induce tolerance to the native protein. The combination of TGF- and one or more of these peptides has the therapeutic effect of inducing and maintaining oral tolerance towards newly introduced proteins, in particular, at the weaning period. The combination can modulate the infant and toddler immune response to allergens.

Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.

Described herein are novel compositions comprising a Cannabis component selected from the group consisting of: a cannabinoid, a flavonoid and a terpenoid; and a protein, selected from the group consisting of whey and a plant protein. According to an embodiment, the Cannabis component is non-covalently bound to the whey or to the plant protein. The plant protein may be selected from the group consisting of: soy protein, pea protein, rice protein, hemp protein, and hops protein or other plant derived protein.

Described herein are novel compositions comprising a Cannabis component selected from the group consisting of: a cannabinoid, a flavonoid and a terpenoid; and a protein, selected from the group consisting of whey and a plant protein. According to an embodiment, the Cannabis component is non-covalently bound to the whey or to the plant protein. The plant protein may be selected from the group consisting of: soy protein, pea protein, rice protein, hemp protein, and hops protein or other plant derived protein.

Provided is a food or beverage product having good taste, with lingering unpleasant bitterness unique to epigallocatechin gallate in the food or beverage product reduced. The content of epigallocatechin gallate and the content of cycloprolyl threonine in the food or beverage product are adjusted to fall within specific ranges.